FDA Approved Camzyos for Pediatric Heart Condition
Children with symptomatic obstructive hypertrophic cardiomyopathy may now access this therapy if they meet weight requirements.
Updated on Sept. 30, 2026 in Heart Disease
The FDA has approved the use of Camzyos capsules for pediatric patients aged 12 to 18 who weigh at least 30 kg. This medication is indicated for those living with symptomatic obstructive hypertrophic cardiomyopathy.
Why it matters
The condition causes the heart muscle to thicken, which narrows the left ventricular outflow tract and impairs blood flow. This approval aims to improve functional capacity and reduce symptoms for a younger patient population.
A Phase 3 clinical study of 44 patients aged 12 to 18 evaluated the change in left ventricular outflow tract pressure during a 28-week trial. The study assessed daily administration of the drug compared to a placebo group.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products and pharmaceuticals.
The details
Obstructive hypertrophic cardiomyopathy creates structural challenges by thickening the heart muscle, which obstructs the left ventricular outflow tract. Camzyos works to modulate the mechanics of the heart muscle. Because of the risk of heart failure, the drug is available only through a restricted Risk Evaluation and Mitigation Strategy program.
Timeline
2022: Camzyos received initial FDA approval for adult patients.
September 30, 2026: The FDA approved Camzyos for pediatric use.
Health Landscape
This approval follows a precedent set by the FDA's orphan drug designation program, which incentivizes the development of therapies for conditions affecting fewer patients. It expands the available treatment options for symptomatic obstructive hypertrophic cardiomyopathy beyond the adult population.
Parents of children diagnosed with this condition should discuss the eligibility criteria and the mandatory risk mitigation program with their cardiologist. Patients and caregivers should remain alert for side effects, as dizziness and fainting occurred in more than 5% of study participants.
The takeaway
Camzyos is now a treatment option for qualifying pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. Given the medication carries a boxed warning for heart failure, families must strictly adhere to the safety monitoring protocols established by their medical team.
Further reading
For more on managing structural heart conditions, visit our Heart Disease section.
Source note: This article includes information reported by U.S. Food and Drug Administration.
